GI in Pregnancy: Incidental and Pre-Existing Liver Disease

0:00Welcome to Board Pearls. This is episode four of six of the GI in Pregnancy chapter, in the Special Populations and Acute or Supportive Care module. In this episode we cover the incidental liver disease of pregnancy: viral hepatitis with virus-specific transmission and antiviral decisions, and pre-existing liver disease where pregnancy changes the management.

0:21The last episode covered the pregnancy-specific syndromes, where delivery is the treatment. This episode takes the other half, the hepatic disease that is not caused by pregnancy but is reshaped by it.

0:33Viral hepatitis in pregnancy turns on virus-specific decisions, each driven by transmission mechanism and antiviral safety. Hepatitis A first. Incidence in pregnancy matches the general population, and pregnancy does not alter the natural history. Acute HAV in pregnancy can be associated with preterm labor and premature rupture of membranes, but maternal and fetal outcomes are generally good. The HAV vaccine is safe in pregnancy because it is an inactivated virus with no replicative capacity. Post-exposure immunoglobulin is also safe. If HAV infection occurs within two weeks of delivery, the infant receives HAV immunoglobulin to provide passive antibody protection until the infant clears maternal-derived virus.

1:21Hepatitis B is the high-yield one, because it is where you make a pregnancy-specific therapeutic decision. Vertical transmission risk is dose-dependent on maternal viremia. Without prophylaxis, an HBeAg-positive mother has roughly ninety percent transmission, and an HBeAg-negative mother has ten to forty percent. The dominant risk is peripartum exposure of the infant to maternal blood and secretions during delivery. The actionable lab is not HBeAg, though. It is HBV DNA, because viral load predicts transmission better. The threshold for adding maternal antiviral therapy is HBV DNA above two hundred thousand international units per milliliter, roughly ten to the sixth copies per milliliter, by week twenty-eight.

2:07The drug is tenofovir disoproxil fumarate, three hundred milligrams orally daily, started at twenty-eight to thirty-two weeks. Why this drug. TDF has a high genetic barrier to resistance, no resistance reports in clinical use, and a substantial pregnancy safety record from HIV experience. Lamivudine and telbivudine are no longer recommended because of high resistance rates with prolonged use. Tenofovir alafenamide does not yet have established pregnancy efficacy data and is not first-line.

2:39All infants of HBsAg-positive mothers receive HBIG plus the first HBV vaccine dose within twelve hours of birth, with the vaccine series completed at one and six months. The combined prophylaxis is testable, because the mechanism is mechanistically additive. HBIG provides immediate passive antibodies, anti-HBs, that neutralize circulating virus during the window before the infant develops active immunity. The vaccine drives the infant to produce active anti-HBs over the following weeks. Together they take transmission in an HBeAg-positive mother from over ninety percent down to under five percent. Cesarean delivery has not been shown to reduce vertical transmission and is not recommended for HBV alone. Amniocentesis is avoided because instrumentation may increase transmission risk. Breastfeeding is safe even with cracked or bleeding nipples, because the infant is already protected by HBIG plus vaccine.

3:36Maternal antiviral therapy can be discontinued at delivery or six weeks postpartum if no other indication exists. Liver enzymes are monitored for six months postpartum, because postpartum HBV flare occurs in three and a half to twenty-five percent of cases. The reason is immune-tolerance reversal of pregnancy. The Th2 dominance of pregnancy lifts at delivery, cellular immunity returns, and the patient mounts an immune attack on her own infected hepatocytes that had been tolerated during pregnancy. Postpartum flares can occasionally clear HBsAg, which is a rare bright side. Women with advanced fibrosis do not stop antiviral therapy, because the decompensation risk of a flare in that group is unacceptable.

4:17Hepatitis C next. Vertical transmission is approximately five percent without HIV coinfection and ten to fifteen percent with HIV coinfection, because HIV-driven impairment of cellular immunity allows higher HCV viremia. Mode of delivery does not affect transmission, so cesarean delivery is not indicated for HCV alone. Invasive fetal monitoring, episiotomy, and prolonged rupture of membranes are avoided, because each exposes fetal blood and mucosal surfaces to maternal blood. Direct-acting antivirals are not approved during pregnancy in the US because of limited safety data. Treatment is deferred until after pregnancy, or done before conception.

5:00Ribavirin is the contraindication that is essentially absolute. It is highly teratogenic through mutagenic disruption of nucleic acid synthesis. Both women and men must use two forms of contraception for six months after the last dose. Anti-HCV antibody testing in infants is not useful before maternal antibodies clear, because passively transferred maternal IgG persists. HCV RNA at two to six months of age, and HCV antibody after eighteen months, are the appropriate diagnostic tests in exposed infants. Up to ten percent of women have spontaneous HCV clearance postpartum, so HCV RNA is rechecked after delivery. Breastfeeding is safe unless there is nipple trauma or HIV coinfection. All pregnant women are screened for HCV at the first prenatal visit per modern guidelines, the opioid-epidemic-driven update.

5:53Hepatitis E is the one with genotype-specific severity. Genotypes one and two are fecal-oral water-borne strains endemic in South and Central Asia, sub-Saharan Africa, and Mexico. These are the strains that cause twenty to thirty-three percent maternal mortality in third-trimester pregnancy, with approximately three thousand stillbirths worldwide annually. Genotype three is the zoonotic strain prevalent in industrialized countries, acquired from undercooked pork and game meat. It produces a generally self-limited illness without the pregnancy-specific severity of genotypes one and two. So the geographic and exposure history predicts which HEV genotype the patient has and whether the high-mortality risk applies. HEV viral loads are higher in pregnant than non-pregnant women regardless of genotype. The mechanisms proposed for the severe genotype one and two outcomes are two. One is nutritional cofactors, especially folate deficiency. The other is the immunologic shift of pregnancy, the Th2 dominance with decreased cellular immunity that allows tolerance of fetal alloantigens. Together they impair viral clearance. Ribavirin and interferon-alpha are effective for HEV in non-pregnant patients but both are contraindicated in pregnancy. Ribavirin is teratogenic, interferon is abortifacient. Management is supportive, with attention to fluid balance, coagulopathy, and ICU admission for fulminant cases.

7:22Disseminated HSV is the fourth and most testable trap in this section. It produces an anicteric liver failure. Transaminases are markedly elevated, twenty-five to forty times the upper limit of normal, but bilirubin stays below three. Vesicular rash is absent in approximately half of cases, which is why HSV is frequently missed on initial assessment. About a quarter of disseminated HSV cases occur in pregnancy.

7:48The rule is empiric. Intravenous acyclovir is started before HSV PCR results return in any pregnant patient with acute hepatitis, especially with fever and upper respiratory symptoms. The pathology progresses rapidly, and the cost of waiting for confirmation is fulminant hepatic failure. Untreated mortality is approximately thirty to fifty percent. Empirical acyclovir cuts that to roughly eight to twenty-five percent. That is the empirical foundation for treating any pregnant patient with the suggestive transaminase pattern as HSV until proven otherwise. Acyclovir is well-studied in pregnancy and safe across all trimesters. Histology shows patchy necrosis, minimal inflammation, and viral inclusion bodies. The triad that should pull HSV to the top of the differential is fever, very high transaminases, and a near-normal bilirubin in a pregnant patient who may or may not have skin findings.

8:42Now the last section. Pre-existing liver disease in pregnancy. The organizing principle is that pregnancy modulates immune activity, changes hepatic synthetic and metabolic demand, and alters drug pharmacokinetics. Disease-specific decisions follow from those mechanisms.

9:00Autoimmune hepatitis benefits from the pregnancy-induced Th2 shift, which often reduces disease activity during pregnancy. But the abrupt return of cellular immunity postpartum produces flares in thirty to fifty percent of patients. So withdrawing immunosuppression during pregnancy is not appropriate, because the disease can flare during pregnancy in up to twenty percent of patients, and intrapartum flares carry an eleven percent maternal death or transplant risk. Prednisone and azathioprine are continued through pregnancy. Azathioprine is acceptable despite its category D label, because the fetal liver lacks inosine triphosphate pyrophosphatase, the enzyme needed to convert azathioprine to its active 6-thioguanine metabolite. So fetal exposure to active drug is minimal, even though the prodrug crosses. Clinical experience supports safety. Older literature suggested a small first-trimester cleft palate signal with prednisone, but recent cohorts show no increased risk.

10:01Mycophenolate is strictly contraindicated. It inhibits inosine monophosphate dehydrogenase and blocks guanosine nucleotide synthesis required for fetal proliferation. The FDA black-box warning is for cleft lip and palate, distal limb, heart, esophagus, and kidney anomalies, and it enforces a six-month pre-conception washout. Men taking mycophenolate also avoid fathering children for ninety days after discontinuation. Liver enzymes are monitored each trimester, with closer monitoring every two to four weeks for the first six months postpartum to catch flares early.

10:35Primary biliary cholangitis next. About a third of PBC diagnoses are made during pregnancy, because the pruritus prompts investigation. Baseline total bile acids are checked in the first trimester, so that later pruritus can be distinguished from superimposed intrahepatic cholestasis of pregnancy. UDCA is continued through pregnancy, category B, with the same mechanism it has in ICP. Pruritus may worsen during pregnancy and is managed with cholestyramine, rifampin, or S-adenosyl-L-methionine. Postpartum flares happen in sixty to seventy percent of patients. Cholestasis impairs fat-soluble vitamin absorption, so vitamin K levels are monitored and parenteral vitamin K is given when deficient. Obeticholic acid and fibrates are not recommended in pregnancy because of limited safety data.

11:22Primary sclerosing cholangitis is managed supportively. Pruritus control with cholestyramine or rifampin. Fat-soluble vitamin replacement. Surveillance for cholangiocarcinoma and dominant strictures. ERCP is reserved for cholangitis, or a dominant stricture with progressive cholestasis or jaundice, and is timed to the second trimester when feasible, with limited fluoroscopy and lead shielding. Routine surveillance imaging continues.

11:49Wilson disease is the one with the rule that is absolute. Chelation must continue. Cessation can precipitate acute liver failure from copper accumulation. Trientine is preferred over D-penicillamine in pregnancy, because penicillamine has a higher historical teratogenic signal in animal studies and in cumulative human reports. Zinc maintenance is preferred where the disease is well-controlled at conception, because zinc has the lowest fetal exposure of the options. The chelation dose is reduced by twenty-five to fifty percent in the third trimester. Roughly seven hundred fifty to one thousand milligrams per day in the first and second trimesters, dropping to five hundred milligrams per day in the third. The reason is two-sided. Maintain enough chelation to keep maternal copper safe, but allow some copper for fetal neurologic and connective tissue development, and to promote maternal wound healing for delivery. Trientine can chelate iron, so iron supplementation may need to be increased. Prenatal vitamins are avoided, because they contain copper that the patient is actively trying to keep low.

12:56Wilson disease has a specific contraception rule that follows directly from the mechanism, and it is testable. Copper IUDs are contraindicated, because local copper exposure overloads the patient's compromised copper handling. Levonorgestrel IUDs are the preferred long-acting reversible method, because they deliver no copper and provide effective contraception during the period when chelation needs to remain stable. Inadequately treated Wilson disease causes infertility, because copper overload prevents embryo implantation through endometrial toxicity, which is part of why treatment continuity matters even outside pregnancy. Breastfeeding is not recommended on D-penicillamine, because the drug crosses into breast milk and chelates copper that the ATP7B copper transporter would normally deliver to milk, leaving the infant copper-deficient. All Wilson medications carry some breast-milk excretion risk.

13:48Cirrhosis. Successful pregnancy is possible in well-compensated cirrhosis, but decompensated cirrhosis requires careful counseling, because hypothalamic-pituitary dysfunction produces amenorrhea and infertility, though pregnancy can still occur. A MELD greater than ten has approximately eighty-three percent sensitivity and specificity for predicting pregnancy decompensation, and the complication rate is roughly ten percent above that threshold.

14:15Portal hypertension worsens late in pregnancy, because plasma volume expansion further raises portal pressure. Variceal bleeding risk rises, especially in the second trimester and peripartum. Roughly twenty to twenty-five percent in those with existing varices. Maternal bleeding mortality from variceal hemorrhage is ten to eighteen percent. So variceal screening is performed within twelve months of conception. If it was not done preconception, EGD is done early in the second trimester. Large varices receive prophylactic non-selective beta blocker or band ligation. Propranolol is preferred over nadolol, because nadolol's long half-life produces fetal bradycardia and low birth weight. Active variceal hemorrhage is managed with band ligation, octreotide, and ceftriaxone prophylaxis, the same triad as in non-pregnant cirrhotic UGIB. Vasopressin is avoided in pregnancy, because it activates V1 receptors on myometrium and induces uterine contractions and preterm labor. That is the pregnancy-specific exclusion from the standard variceal vasoactive menu.

15:20Splenic artery aneurysm has a two point six percent prevalence in cirrhotic pregnancy, and rupture is often fatal. Screening with ultrasound during pregnancy is appropriate. Aneurysms above two centimeters are at highest risk, although half of pregnancy ruptures are below that. Postpartum hemorrhage occurs in seven to ten percent of cirrhotic pregnancies. Delivery is at a tertiary center.

15:46Post-liver-transplant pregnancy is delayed at least one year post-transplant or post-rejection episode, to allow stable graft function on a stable maintenance regimen. Menstrual return occurs within ten months of transplant in ninety percent of recipients. Tacrolimus, cyclosporine, prednisone, and azathioprine are continued through pregnancy. Trough monitoring every two to four weeks is needed, because volume expansion lowers calcineurin inhibitor levels and dose adjustment is required. mTOR inhibitors, sirolimus and everolimus, are avoided because limited pregnancy data show approximately thirty-one percent miscarriage signal. Mycophenolate is absolutely contraindicated and must be switched to azathioprine before conception. Gestational diabetes happens in about ten percent of post-transplant pregnancies, and hypertensive disorders in twenty-two to seventy-three percent. Maternal-fetal medicine plus high-risk obstetrics co-management is standard.

16:44Pull the incidental half together. Viral hepatitis turns on virus-specific transmission and antiviral safety. HBV vertical transmission is dose-dependent on maternal viremia, and TDF plus HBIG-plus-vaccine cuts transmission decisively. HCV is screened universally but treated outside pregnancy, with ribavirin absolutely contraindicated. HEV severity follows genotype and geography. And disseminated HSV with high transaminases and low bilirubin gets empiric acyclovir before PCR returns. The pre-existing liver diseases follow the immune-pharmacokinetic principle, continue what is working and swap out the teratogens, with the testable specifics being mycophenolate out and azathioprine acceptable because the fetus cannot activate it, trientine over penicillamine in Wilson with the copper-IUD exclusion, and propranolol not nadolol for variceal prophylaxis with vasopressin off the table.

17:41The next episode takes the same logic into the luminal GI disease of pregnancy, beginning with inflammatory bowel disease, where the biologics continue through delivery and FcRn-mediated placental transfer distinguishes the anti-TNF agents from certolizumab.

17:56For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode four of six of chapter thirty five, and I'll see you in the next one.